Skip to main content
Clinical Trials/IRCT20200522047542N1
IRCT20200522047542N1
Recruiting
Phase 1

Effect of inhaled corticosteroids in the treatment of anosmia in patients with COVID-19

Mashhad University of Medical Sciences0 sites70 target enrollmentTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Mashhad University of Medical Sciences
Enrollment
70
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with COVID\-19 who have been referred or admitted to Qaem, Imam Reza, or Shariati Hospital diagnosed with a protocol defined by the World Health Organization.
  • People who have not experienced any signs of reduced sense of smell and taste for at least 2 weeks before the onset of the first manifestation of Covid\-19\.
  • People who were diagnosed with hyposmia or anosmia.

Exclusion Criteria

  • People with certain underlying conditions (such as Parkinson's, Alzheimer's, severe nutritional disorders, acute rhinitis, acute catarrhal sinusitis, SICA syndrome (especially after radiation), nasal mucosal congestion, for example after rhinoplasty, olfactory nerve damage in trauma, etc., which are exposed to the reduction of the sense of smell independent of the coronavirus, as well as, people who experience other viral and bacterial infections simultaneously with COVID\-19
  • People with a history of asthma and allergies are excluded
  • Participants who refused to participate in follow\-up measurements, provide data, or give consent considered withdrawn.

Outcomes

Primary Outcomes

Not specified

Similar Trials